



Medicines & Healthcare products
Regulatory Agency



MHRA

10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom
[gov.uk/mhra](https://www.gov.uk/mhra)

Prof C Butler
UNIVERSITY OF OXFORD
NUFFIELD DEPARTMENT OF PRIMARY CARE HEALTH SCIENCES,
RADCLIFFE OBSERVATORY QUARTER, WOODSTOCK ROAD
OXFORD
OX2 6GG
UNITED KINGDOM

06/04/2022

Dear Prof C Butler

THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 S.I. 2004/1031

Our Reference:	CTA 21584/0452/001-0004
IRAS ID:	1004274
Product:	Molnupiravir, Paxlovid
Protocol Number:	PANORAMIC
Substantial Amendment Code Number:	Substantial Amendment 03

ACKNOWLEDGEMENT OF AMENDMENT

Thank you for your notice of amendment, received on 05/04/2022. The information you provided to support your request is complete and therefore your request is valid.

Your request will be assessed and you will be notified of the Licensing Authority's decision, and Research Ethics Committee's decision (where applicable), within 35 days.

Please quote the IRAS ID, CTA number and your amendment code in any further communications relating to this submission.

Yours sincerely,

CT Submission
MHRA